Adding C-reactive protein (CRP) level to conventional cardiovascular risk models has been suggested to improve risk prediction for cardiovascular events. However, evaluation of the potential impact of CRP measurement in cardiovascular risk management will require studies designed to quantify the effect of additional CRP assessment on medical decision-making, patient outcomes, and cost-effectiveness.
Sanne A E Peters, Frank L J Visseren, Diederick E Grobbee. Biomarkers. Screening for C-reactive protein in CVD prediction. Nature reviews. Cardiology. 2013 Jan;10(1):12-4
PMID: 23165068
View Full Text